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Abstract 
Background: Major depressive disorder (MDD) is a disabling mood disorder and, despite a known heritable component, a 
large meta-analysis of GWAS revealed no replicable genetic risk variants. Given prior evidence of heterogeneity by age-at-
onset (AAO) in MDD, we tested whether genome-wide significant risk variants for MDD could be identified in cases subdivided 
by AAO.  
Method: Discovery case-control GWASs were performed where cases were stratified using increasing/decreasing AAO-cutoffs; 
significant SNPs were tested in nine independent replication samples, giving a total sample of 22,158 cases and 133,749 
controls for sub-setting. Polygenic score analysis was used to examine if differences in shared genetic risk exists between 
earlier and adult onset MDD with commonly co-morbid disorders of schizophrenia, bipolar disorder, Alzheimer’s disease, and 
coronary artery disease. 
Results: We identify one replicated genome-wide significant locus associated with adult-onset (>27 years) MDD (rs7647854, 
OR=1.16, 95%CI=1.11-1.21, p=5.2x10-11). Using polygenic score analyses, we show that earlier-onset MDD is genetically more 
similar to schizophrenia and bipolar disorder than adult-onset.  
Conclusions: We demonstrate that using additional phenotype data previously collected by genetic studies to tackle 
phenotypic heterogeneity in MDD can successfully lead to the discovery of genetic risk factor despite reduced sample size. 
Furthermore, our results suggest that the genetic susceptibility to MDD differs between adult- and earlier-onset MDD, with 
earlier-onset cases having a greater genetic overlap with schizophrenia and bipolar disorder.  
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Introduction 
Major depressive disorder (MDD) is a highly prevalent and heterogeneous disorder (1). With most individuals experiencing 
recurrent episodes throughout life (2), MDD is now the second leading cause of disability worldwide (3). MDD is defined by 
low mood and energy, inability to experience enjoyment, changes to eating and sleep patterns, feelings of guilt or 
worthlessness, and suicidal thoughts (4). Along with excess mortality and increased risk of suicide (5), MDD is associated with 
worse clinical outcomes when co-morbid with health problems such as cardiovascular disease and cancer (6; 7). While the 
heritability is estimated at 31-42% (8), the causal variants remain elusive: a recent large mega-analysis with over 9000 MDD 
cases failed to identify any replicable associations (9), despite successes in similarly sized studies of schizophrenia and bipolar 
disorder (10; 11). This lack of biological markers may be one of the causes for the well established underfunding of research 
into MDD relative to its economic and health burden (12), and the reported stigmatization of sufferers (13).  
 
However, several differences exist between MDD and other psychiatric disorders where replicable genetic associations have 
been identified, including higher prevalence, greater diagnostic uncertainty, lower heritability, and, crucially, increased 
heterogeneity. One known source of heterogeneity that may contribute substantially is age at onset (AAO). Onset can occur at 
any stage of life, yet many factors associated with MDD are either age specific or restricted. These include biological events 
such as puberty, menopause and dementia, and environmental risk factors including childhood maltreatment, childbirth, and 
divorce. Earlier onset is associated with increased risk in first-degree relatives and higher heritability (14-18). Considerable 
differences in the transmission of early versus late onset MDD have also been reported (19; 20), with some studies suggesting 
the effects of novel genetic risk factors for MDD appearing later in life (21; 22). 
 
Here we build on the previous mega-analysis of Major Depressive Disorder Working Group of the PGC (PGC-MDD), using AAO 
to stratify cases within a sample of 8920 cases and 9521 controls, with the goal of reducing heterogeneity. For each of the 
nine PGC-MDD samples (23-30), cases were ordered by AAO within study and divided into eight groups (octiles). Genome-
wide association analysis of cases in these octiles was performed systematically against controls for 1 235 109 autosomal 
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single nucleotide polymorphisms (SNPs). We examined three analytic strategies: (a) genetic variants specific to early-onset 
MDD; (b) risk variants specific to late-onset; and (c) restricting to the intermediate four octiles excluding the 25% of cases at 
either extreme of AAO to test for potential heterogeneity introduced from very early or very late onset. Significantly 
associated SNPs were taken forward for replication in nine studies comprising 13 238 cases and 124 230 controls. We also 
examined the differences between early and late onset MDD in their shared heritability with commonly co-morbid disorders 
of schizophrenia, bipolar disorder, Alzheimer’s disease, and coronary artery disease, in order to identify differences in genetic 
etiologies across onset groups.  
Methods and Materials: 
Description of samples 
Full details of the studies that form the PGC-MDD are given in the supplementary materials of the original data analysis (9).  
Briefly, these nine MDD studies (23-30) conducted genome-wide genotyping on individual subjects of European ancestry. 
Cases were required to have diagnoses of DSM-IV lifetime MDD established using structured diagnostic instruments from 
direct interviews by trained interviewers or clinician-administered DSM-IV checklists. Two studies required recurrent MDD and 
one recurrent, early-onset MDD. Studies ascertained cases mostly from clinical sources, and controls were largely randomly 
selected from the population and screened for lifetime history of MDD. This led to a total of 9238 cases and 9521 controls 
with genotype information.  
AAO phenotype 
Age at onset (AAO) was defined as the age at which individuals first had symptoms that met the criteria of MDD, and was self-
reported in all studies. Of the original 9238 cases included in the sample, 8920 (95.6%) had a reported AAO. Cases reporting an 
AAO older than the recorded age at interview were removed from the analysis (n=17). Within each study, cases were ordered 
by AAO, and then divided into octiles, giving approximately 1000 cases per octile.  Octiles were defined within study to 
account for differences in case ascertainment. We noted a wide range in AAO between studies ascertaining recurrent 
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depression using the same instrument, indicating that the precise setting (study, clinic, country) was important; we therefore 
chose to order cases by AAO within study, rather than across studies, or by absolute AAO cut-offs.  This strategy will identify 
genetic variants that were specific to early or late onset, relative to the mean AAO of the recruited cases. For secondary 
analysis of sex specific effects, octiles were additionally defined within only males and females for analysis of sex-specific 
effects, and for recurrent depression that has a higher heritability. These octiles will be referred to as O1-8, with O1 
representing the earliest onset octile, and O8 representing the latest onset octile. The GenRED study only recruited MDD 
cases with an age at onset below 31 years (25). We compared the distribution of AAO in GenRED with other similar studies 
(STAR*D, RADIANT-UK) and estimated that GenRED recruited the youngest 62% of all possible MDD cases, with older cases 
absent from the study (Supplementary Figure 1).  GenRED cases were ordered by AAO, and assigned to the appropriate 
octiles O1-5, with no cases present in O6-8.   
Quality Control 
Genotyping was described in the supplementary materials in the original analysis.11 All samples were genotyped with single 
nucleotide polymorphism (SNP) arrays of at least 200 000 SNPs. SNPs were removed for missingness >0.02, case–control 
difference in SNP missingness >0.02, SNP frequency difference from HapMap3 >0.15, or deviation from Hardy–Weinberg 
equilibrium in controls (exact p<1.0x10-6). Subjects were removed for excessive missingness (>0.02), identical or closely 
related to any subject in any sample (pi-hat > 0.2 based on common autosomal SNPs), or if there was evidence for diverging 
ancestry. Ancestry was estimated using multidimensional scaling applied to 8 549 SNPs directly genotyped in all samples and 
in approximate linkage equilibrium. Imputation was performed using Beagle 3.0.440 (31) with the CEU HapMap3 data (32) to 
impute 1 235 109 autosomal SNP allele dosages. The first 20 ancestry–informative principal components were included as 
covariates, along with an indicator for each study.  
Genome-wide association analysis 
Genome-wide association analysis was performed in PLINK using logistic regression to test the association between case 
control phenotype and imputed SNP dosages under an additive model (33). Genotyping coordinates are given in NCBI Build 
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36/UCSC hg18. Quality control was conducted separately for each sample. To test for SNPs associated with distinct aspects of 
MDD based on AAO, we performed three hypothesis-driven analyses (Supplementary Figure 2). The first analysis targeted 
those SNPs associated with early-onset MDD in a series of genome-wide association analyses, initially looking at the earliest 
onset cases (O1) against all controls, then the combined O1-2 cases against controls, then O1-3, etc. until all cases were 
included. This approach was based on the Sequential Additions Method (34), developed to take account of a quantitative trait 
that is measured in cases but not controls and provide an estimate of the best phenotype definition for future studies. The 
second analysis was similarly performed to examine those SNPs associated with later onset MDD, but reversing the procedure 
(i.e., first looking at the latest onset cases (O8) against all controls, then O7-8 against controls, then O6-8, etc. until all cases 
were included). The third analysis tested if the extremes of AAO, both early and late, were introducing heterogeneity to the 
cases excluding O1-2 and O7-8, leaving those cases with onset within the inter-quartile range of AAO for each study (O3-6). 
We then tested O3-6 cases against all controls. Each analysis was performed using all cases; male cases only; female cases 
only; and recurrent cases only. Analyses of all, or almost all, cases (O1-O8, O1-O7, or O2-8) were used to identify SNPs that 
reached greatest significance without an AAO specific effect, and so were omitted from further analysis as would have been 
captured in the primary analysis of this data. In total, 52 genome-wide analyses were performed (=(6+6+1)x4), making the 
standard multiple testing threshold of p<5.0x10-8 for genome-wide significance anti-conservative. We applied a Bonferroni 
correction for 52 analyses to genome-wide significance, which is highly conservative since many analyses were highly 
correlated.  For replication, we selected SNPs with p<9.5x10-10 in the discovery sample in more than one analysis (either by 
sex, recurrence or inclusion of octiles); the combination of cases that yielded the greatest significance was chosen as the basis 
for replication.  This analysis strategy uses AAO as a stratifying variable to construct subsets of cases which may be more 
homogeneous and identify SNPs that are associated with susceptibility to MDD with a restricted AAO; it does not identify SNPs 
that control MDD AAO, which would require a case-only analysis of AAO as a quantitative trait.     
Replication analysis 
Five replication samples used in the primary analysis of this dataset had AAO information available (TwinGene (35), 
GenREDII/DepGenesNetwork (25), deCODE (9), PsychCoLaus (36), SHIP-LEGEND (37)). The GenPod/NEWMEDS and Harvard 
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I2B2 studies, which appeared in the replication of the primary analysis of this dataset, did not have AAO data available and 
were not included. Four new replication studies were available ((1) a collection of samples available through the University of 
Münster (38; 39); (2) a combination of RADIANT cases from Denmark (40), the Danish DEMO and PRISME studies of MDD (41; 
42), and a set of Danish population controls; (3) the CONVERGE study of MDD cases and controls recruited in China (18; 43; 
44); and (4) the Generation Scotland study which included measures on MDD (45)). These are outlined, alongside the 
definitions of AAO, in the Supplementary Methods. Due to the early median AAO in the GenREDII/ DepGenesNetwork, an 
artificial ‘median’ was introduced at age 27, based on the median for the discovery samples. Those SNPs that passed our 
threshold of p<9.5x10-10 in the discovery sample were tested for association within these nine replication studies. Due to 
differences in availability of genome-wide genotype data, each study was genotyped and/or imputed separately.  A fixed-
effect inverse variance based meta-analysis of the replication studies was performed using METAL (46). 
Polygenic analysis 
We also examined the association between early/late onset MDD and polygenic risk scores for other psychiatric disorders, as 
this might reflect either shared genetic etiology or phenotypic contamination (47). Polygenic risk scores for schizophrenia 
(9379 cases and 7736 controls) and bipolar disorder (6990 cases and 4820 controls) were created by the PGC, using imputed 
data and removing overlapping controls, ensuring the datasets were completely independent (10; 11). Alzheimer’s disease 
polygenic risk scores were obtained from Genetic and Environmental Risk for Alzheimer’s disease (GERAD) Consortium (48) 
and the coronary artery disease scores from the CARDIoGRAM Consortium (49). The imputed GERAD sample comprised 3177 
cases and 7277 controls, and the CARDIoGRAM consortium consisted of 22 233 cases and 64 762 controls. All four disorders 
were chosen for their previous genetic and epidemiological evidence of overlap with MDD (50-52). 
Polygenic risk scores were calculated for MDD cases and controls, summing the number of risk alleles carried, weighted by the 
natural log of their odds ratio in the original genome-wide association study. Score SNPs with low minor allele frequency 
(MAF<0.02) or in the major histocompatibility complex (MHC) region were removed, and score datasets were pruned for 
linkage disequilibrium using the clumping command in PLINK to remove SNPs within 500kb and r2 > 0.25 with a more 
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significantly associated SNP. Seven scores were calculated, using a p-value threshold (PT) to restrict to the most significant 
SNPs in their original genome-wide association analysis (PT < 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5). Logistic regression was used to 
test for association between polygenic risk scores and case control status using four different case-control sets (all MDD cases 
vs. controls, O1-3 cases vs. controls, O6-8 cases vs. controls, and O1-3 vs. O6-8 cases) with 20 population principal 
components and study indicators as covariates. We calculated the proportion of variance explained (Nagelkerke’s R2) by 
subtraction of a full model (covariates + RPS) score from a reduced model (covariates only). The GenRED sample was not 
included in the analysis as they had no cases within the O6-8 analysis; the Bonn-Mannheim study was not included in the 
analysis of Alzheimer’s disease or coronary artery disease due to overlapping controls with the respective consortia. 
Results 
Summary of AAO  
After quality control the sample consisted of 8920 MDD cases with AAO information and 9519 controls with 1 235 109 SNPs. 
The median AAO across all cases excluding GenRED was 27 years old (IQR=18-38) and the mean 28.9 (SD 13.64), reflecting the 
long tail of older onset cases (Figure 1 and Supplementary Figure 3). Median AAO by study ranged from 20 - 37 years (16 for 
GenRED which recruited only recurrent cases with onset no greater than 30), with the German samples having a slightly older 
onset. Mean AAO was lower for recurrent cases than non-recurrent, 27.1 to 33.0 (p<0.001, correcting for study and excluding 
GenRED). AAO was also older for males with a mean of 29.0 compared to 26.7 in females (p<0.001). 
Genome-wide association analysis 
Our analysis of both early and late-onset octiles and the intermediate median of AAO excluding extreme-AAO cases led to four 
tests passing our significance cut off for replication (p<9.5x10-10), all for associations with SNP rs7647854 on chromosome 3. 
The only genome-wide significant association for this SNP was in the 50% oldest onset cases against all controls (O5-8: 
p=3.4x10-11, Supplementary Figure 4 & 5). As a secondary analysis of this SNP, we split cases within our discovery sample into 
non-overlapping quartiles and analyzed against controls. This showed a strong association in the oldest quartile (O7-8: 
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p=9.0x10-10, OR=1.37, 95%CI 1.23-1.51; Figure 2), a moderate effect in the 3rd quartile (O5-6: p=2.0x10-5, OR=1.23), and no 
evidence of association in the two youngest quartiles (O1-2: p=0.07, OR=1.09; O3-4: p=0.30, OR=1.06). Further, when the 
inclusion threshold for AAO was increased one year at a time within each study (until only 100 cases remained), we observed 
a gradual increase in effect size for rs7647854 in all studies as the analysis was restricted to progressively later onset cases 
(Supplementary Figure 6). Analysis by sex or recurrence revealed no additional findings.   
Replication analysis 
Given the results from our discovery data set, rs7647854 was taken forward for replication in nine independent studies (Table 
1). The SNP was tested for association with oldest half of MDD cases (O5-O8), since this analysis attained the smallest p-value 
in the discovery studies. The SNP was either directly genotyped or imputed at high confidence across all studies 
(Supplementary Table 1). The SNP was significantly associated with MDD in a meta-analysis of these studies, with a p value of 
7.5x10-4 and an odds ratio of 1.10 (total number of MDD cases = 6,107 and total number of controls 124,230) (Table 2; 
Supplementary Figure 5). Meta-analysis of the combined discovery sample with individual replication studies gave a p-value 
of 5.2x10-11 and an odds ratio of 1.16 (95%CI 1.11-1.21), surpassing genome-wide significance.  
Polygenic analysis of co-morbid illnesses 
In the PGC MDD discovery studies, polygenic risk scores for bipolar disorder (BPD) and schizophrenia (SCZ) were significantly 
associated with early-onset MDD. Restricting to only early-onset cases (O1-3) vs. controls, the amount of phenotypic 
variability explained (BPD R2=0.41%, p=1.4x10-12; SCZ R2=0.67%, p=3.0x10-19) was much greater than for later onset (O6-8) 
cases (BPD R2=0.16%, p=1.9x10-5; SCZ R2=0.14%, p=3.9x10-5; Figure 3). A similar increase in association with late-onset co-
morbid disorders was not seen. Polygenic risk scores for coronary artery disease from the CARDIoGRAM consortium (49) were 
weakly positively associated with MDD, but this was consistent across early and late onset cases, in contrast to BPD and SCZ 
(Coronary artery disease: O1-3 vs. controls, R2=0.05%, p=0.01; O6-8 vs. controls, R2=0.05%, p=0.01; O1-3 vs. O6-8, R2=<0.01%, 
p=0.76; Figure 3). No association with MDD status was seen for the scores generated for Alzheimer’s disease from the GERAD 
Power 15 
 
consortium (48) regardless of AAO (O1-3 vs. controls, R2<0.01%, p=0.868; O6-8 vs. controls, R2=0.02%, p=0.223; O1-3 vs. O6-8, 
R2=0.03%, p=0.157; Figure 3). Full results from these analyses are available in Supplementary Table 2. 
Discussion 
Our analysis of age at onset and the genetic architecture of MDD suggested that AAO specific genetic risk factors exist. 
Unexpectedly, the strongest associations we observed were with the oldest half of MDD cases, where previous analyses have 
focused on early-onset MDD, supported by studies of the genetic epidemiology of MDD. We emphasize that here ‘late’ onset 
MDD was at still a relatively young age (median onset of MDD was at age 27 with 98% of our sample having onset before 60) 
rather than onset in old age. It is clearer to conceptualize later-onset cases here as ‘adult onset’ cases, and we recommend 
that this sub-group should be included in recruitment of future genetic studies, especially as no difference in the heritability 
captured by SNPs was observed for this subtype compared to early onset cases (see Supplementary Table 3). However, 
substantial differences in AAO across studies make it difficult to put a precise age-cut off for this recommended ‘adult onset’ 
MDD.   
 
We show significant association with rs7647854 on chromosome 3, which was associated with the 50% latest-onset cases 
(p=5.2x10-11, OR=1.16). This SNP was identified as the second strongest association in the primary mega-analysis of the PGC-
MDD data set (9), though at a much lower significance and did not replicate (discovery p=6.5x10-7, replication p=0.67). 
Stratifying by AAO leads to much stronger associations in both the discovery and replication samples, despite the reduced 
sample size. Although analyzing across multiple overlapping AAO subtypes runs the risk of over-fitting to maximize 
significance, we observed highly significant associations for this SNP in both discovery and replication sample. Further we also 
observed a gradual increase in effect size as both raw AAO within studies and AAO percentile across studies increased (Figure 
2 and Supplementary Figure 4). That this was seen both for raw AAO within studies and as a percentile, and in both European 
and Chinese ancestry studies across a wide variety of AAO measurement tools suggests that while our cut-off of the 50% latest 
onset cases is arbitrary, the effect exists regardless of exact cut-off used. However this does not rule out the possibility that 
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AAO may be a proxy for a more homogenous subgroup of MDD based on another factor (e.g. an age-specific environmental 
trigger or distinct pattern of symptoms with onset later in life). That median AAO and effect size across studies was not 
significantly correlated (r=0.011, p=0.68) despite greater effect sizes by AAO percentile within studies, suggests that 
differences in measurement of AAO across studies might obscure effects. rs7647854 is intergenic, with flanking genes 
including  C3orf70, VPS8, EHHADH and MAP3K13. C3orf70, VPS8, and MAP3K13 all show evidence of expression in the brain in 
several areas of potential interest for MDD including the hypothalamus, frontal cortex, pituitary and thyroid (GTex; 
http://www.gtexportal.org/) (53). VPS8 and MAP3K13 also show a slight increase in (RNA) expression within various brain 
regions during neo-natal development (Human Brain Transcriptome; http://hbatlas.org/) (54) with maintained expression into 
adulthood.  
 
This genetic association arises with the supposedly less heritable form of adult-onset MDD, although such summary measures 
give no information on the effect sizes of individual SNPs. One potential explanation is greater contamination of early-onset 
MDD cases by individuals misclassified with MDD or having co-morbid disorders. Longitudinal studies show that early-onset 
depressive symptoms predict not just adult depression but also psychosis (e.g. 55), and there is significant genetic overlap 
between MDD and other psychiatric disorders (50). Inclusion of early-onset cases with individuals who will later develop 
schizophrenia or bipolar disorder would reduce the power of genome-wide association studies for MDD, though secondary 
analysis of age at interview did not support this (Supplementary Figure 7). The polygenic risk score results show that early and 
adult-onset MDD cases differ in their genetic susceptibility to bipolar disorder and schizophrenia and suggest that some of the 
heterogeneity in MDD results from the inclusion of early onset cases with a greater genetic overlap or misclassification with 
these disorders. We did not observe a similar pattern of association for two disorders often co-morbid with late-onset MDD, 
Alzheimer’s disease and coronary artery disease (51; 52).  We did, however, show for the first time a genetic overlap between 
MDD and coronary artery disease irrespective of AAO but not for Alzheimer’s disease. We also found that the heritability 
explained by SNPs across the genome for early and late-onset MDD did not significantly differ suggesting, for common 
variants at least, recruiting only early-onset cases would not increase power (Supplementary Table 3). 
Power 17 
 
 
The limitations of our approach are the reduced sample size and multiple testing from stratifying cases into subtypes, and 
requiring potentially less reliable secondary phenotypes to be widely collected. Measures such as AAO rely on self-report, and 
are often assessed differently across studies that can be problematic for comparison. The analyses presented here addressed 
this by analyzing AAO relative to the median of a study, though this assumed each study recruited cases from the same 
distribution of onset with observed differences due to how AAO was defined. Further, the effect of our genome-wide 
associated SNP were consistent in the replication studies, ethnicities and countries, suggesting that differences in 
measurement may not be as much of a limitation as expected, at least in the case of AAO in MDD. The other disadvantage of 
looking at more homogenous groups is the reduction in sample size. However, it has previously been shown that only modest 
increases in effect size may be required to offset the reduction in power from analyzing fewer cases, implying that analyses of 
more homogenous subgroups have the potential to identify novel associations (56).  
 
Our study illustrates the value of using additional phenotypic information on cases in genome-wide association studies. We 
show here that including information on AAO increases the power to detect associations with MDD, and that analyzing 
polygenic risk scores from related diseases enables us to identify sources of phenotypic heterogeneity that may have 
hampered previous genetic studies. In contrast to other approaches that weight cases on AAO (57), our stratification of cases 
on AAO is agnostic to the direction of the phenotypic effect. Our approach uses the additional phenotype data previously 
collected by genetic studies and complements an alternative emphasis on collecting large sample sizes through minimal 
phenotyping. Both strategies will undoubtedly be necessary to identify and characterize different components of the genetic 
architecture of psychiatric disorders. Further, our analysis shows that tackling phenotypic heterogeneity in MDD can 
successfully lead to the discovery of genetic risk factor despite reduced sample size. The identification here of a novel genetic 
risk variant for MDD is of great importance due to both the scarcity of evidence for the underlying biology and its pressing 
economic health burden. 
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Table 1: 
Summary of MDD discovery and replication cohorts. AAO stands for age at onset.  
  Study Country Measure of 
AAO 
Cases 
with AAO  
Controls Median AAO 
Discovery NESDA/NTR (GAIN) The 
Netherlands 
CIDI 1,675 1,765 25 
GenRED US DIGS3 1,020 1,253 16 
GSK Germany SCAN 887 864 36 
MDD2000-QIMR_610 AU CIDI/SSAGA 432 751 26 
MDD2000-QIMR_317 AU CIDI/SSAGA 1,015 960 26 
MPIP Germany Asked at 
interview 
373 537 37 
RADIANT Bonn/Mannheim Germany SCAN 883 1,290 33 
RADIANT UK SCAN 1,407 1,588 20 
STAR*D US Asked at 
interview 
1,228 511 21 
Total  8,920 9,519   
Replication TwinGene Sweden SALT 1,009 8,601 40 
PsyCoLaus Switzerland DIGS 1,358 1,687 33 
SHIP-LEGEND Germany M-CIDI 381 1,827 37 
GenRED2/DepGenesNetworks US DIGS3 1,296 930 17 
University of Münster Germany SCID 402 516 27 
Combined Danish sample Denmark SCAN 461 1,197 31 
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CONVERGE China  5,715 5,537 34 
deCODE Iceland Hospital 
records 
1,005 99,175 39 
Generation Scotland UK SCID 1,611 4,760 30 
Total 13,238 124,230  
Total 22,158 133,749  
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Table 2 
Summary of association with rs7647854, located at 3q27.2 (186359477 base pairs), with odds ratios (OR) for the reference allele, G 
(frequency 0.16) compared to the non-reference allele A.  All results reported are for the oldest half of MDD cases (O5-8), which had the 
strongest evidence for association in the discovery study.  
 
Study No. of MDD cases Number of Controls OR (95% CI) P-value 
Discovery 3,869 9,519 1.30 (1.20-1.40) 3.4x10-11 
Replication  6,107 124,230 1.10 (1.05- 1.17) 7.5x10-4 
Meta-analysis 9,976 133,749 1.16 (1.11-1.21) 5.2x10-11 
 
Power 30 
 
Figure Legends: 
Figure 1: 
Distribution of age at onset across the nine studies included in the discovery analysis. Mid-grey band 
shows interquartile range across all studies excluding GENDEP, which recruited only cases onset at 30 
years or below. 
Figure 2:  
Evidence for association and effect size for rs7647854 on chromosome 3, with cases split into non-
overlapping quartiles by age at onset within discovery studies. 
Figure 3:  
Polygenic risk profile scoring analysis of bipolar disorder, schizophrenia, Alzheimer’s disease and 
coronary artery disease within the MDD discovery studies (excluding GenRED). We calculated the 
proportion of variance explained (Nagelkerke’s R2) by subtraction of a full model (covariates + RPS) score 
from a reduced model (covariates only). 
 
